Count Me In, a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer ...

Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Renal cell carcinoma is the most common form of kidney cancer. It can take time to fully process a diagnosis and what, ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

An expert discusses how third line (3L) systemic therapy for metastatic renal cell carcinoma (mRCC) is guided by prior ...

Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...

What Is Renal Cell Carcinoma? It's the most common type of kidney cancer. Although it’s a serious disease, finding and treating it early makes it more likely that you’ll be cured. No matter ...

The following is a summary of “Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis,” ...

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and ...